Cardiol Therapeutics Class Stock Five Year Return
| CRDL Stock | CAD 2.03 0.01 0.49% |
Cardiol Therapeutics Class fundamentals help investors to digest information that contributes to Cardiol Therapeutics' financial success or failures. It also enables traders to predict the movement of Cardiol Stock. The fundamental analysis module provides a way to measure Cardiol Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardiol Therapeutics stock.
Cardiol | Five Year Return |
Cardiol Therapeutics Class Company Five Year Return Analysis
Cardiol Therapeutics' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Cardiol Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiol Therapeutics is extremely important. It helps to project a fair market value of Cardiol Stock properly, considering its historical fundamentals such as Five Year Return. Since Cardiol Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiol Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiol Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
Cardiol Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, Cardiol Therapeutics Class has a Five Year Return of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Canada stocks average (which is currently at 0.0).
Cardiol Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiol Therapeutics from analyzing Cardiol Therapeutics' financial statements. These drivers represent accounts that assess Cardiol Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiol Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 118.3M | 83.0M | 100.7M | 43.1M | 49.6M | 93.1M | |
| Enterprise Value | 111.5M | 69.1M | 16.9M | (16.3M) | (18.7M) | (17.8M) |
Cardiol Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 149.94 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 263.21 K | ||||
| Price To Book | 15.88 X | ||||
| Price To Sales | 1,274 X | ||||
| Gross Profit | 78.76 K | ||||
| EBITDA | (29.54 M) | ||||
| Net Income | (28.13 M) | ||||
| Cash And Equivalents | 59.47 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 174.34 K | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 24.67 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (25.18 M) | ||||
| Short Ratio | 2.22 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Target Price | 11.0 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 165.65 M | ||||
| Total Asset | 36.7 M | ||||
| Retained Earnings | (142.58 M) | ||||
| Working Capital | 51.63 M | ||||
| Net Asset | 36.7 M |
About Cardiol Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiol Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiol Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiol Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardiol Stock
Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.